Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Adverum Biotechnologies, Inc.ADVM · Entity 71889 | SVP, Chief Medical Officer | February 15, 2018 | February 20, 2018 |
| BIOMARIN PHARMACEUTICAL INCBMRN · Entity 2404 | Director | June 02, 2026 | June 04, 2026 |
| Cardiff Oncology, Inc.TROV · Entity 6917 | Director | June 20, 2019 | June 24, 2019 |
| HALOZYME THERAPEUTICS, INC.HALO · Entity 793 | SVP and Chief Medical Officer | February 22, 2017 | February 24, 2017 |
| IOVANCE BIOTHERAPEUTICS, INC.IOVA · Entity 2090 | Director | June 16, 2026 | June 18, 2026 |
| Passage BIO, Inc.PASG · Entity 7829 | Director | May 19, 2026 | May 21, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Adverum Biotechnologies, Inc.
Report date February 15, 2018 · Filed February 20, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.40 · Expires 2028-02-14 | Direct | 160,000 |
Reported balance
After 2018-02-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-02-15 · Grant · Acquired 160,000 · Balance 160,000 F1: Twenty-five percent (25%) of the total number of shares subject to the option vest and become exercisable on the first anniversary of February 15, 2018 (the "Vesting Commencement Date"), and 1/48 of the total number of shares subject to the option vest and become exercisable each month thereafter, such that all of the shares subject to the option shall become vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service with the Issuer on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Twenty-five percent (25%) of the total number of shares subject to the option vest and become exercisable on the first anniversary of February 15, 2018 (the "Vesting Commencement Date"), and 1/48 of the total number of shares subject to the option vest and become exercisable each month thereafter, such that all of the shares subject to the option shall become vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service with the Issuer on each such vesting date.
BIOMARIN PHARMACEUTICAL INC
Report date June 02, 2026 · Filed June 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 21,040 |
Reported balance
After 2026-06-02 transaction · row 1
1 source rowRow 1 · 2026-06-02 · Grant · Acquired 7,490 · Balance 21,040 F1: Restricted stock units granted on June 2, 2026. Price not applicable. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units granted on June 2, 2026. Price not applicable.
Cardiff Oncology, Inc.
Report date June 20, 2019 · Filed June 24, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $2.48 · Expires 2029-06-20 | Direct | 46,019 |
Reported balance
After 2019-06-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-06-20 · Grant · Acquired 44,734 · Balance 46,019 |
HALOZYME THERAPEUTICS, INC.
Report date February 22, 2017 · Filed February 24, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $12.07 · Expires 2027-02-22 | Direct | 72,925 |
Reported balance
After 2017-02-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-02-22 · Grant · Acquired 72,925 · Balance 72,925 F1: This option vests one-fourth on such date and then 1/48th monthly thereafter. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 45,568 |
Reported balance
After 2017-02-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-02-22 · Grant · Acquired 45,568 · Balance 45,568 F2: This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: This option vests one-fourth on such date and then 1/48th monthly thereafter.
F2: This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary thereafter.
IOVANCE BIOTHERAPEUTICS, INC.
Report date June 16, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Deferred Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 90,316 |
Reported balance
After 2026-06-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-16 · Grant · Acquired 90,316 · Balance 90,316 F1: Each deferred restricted stock unit ("DRSU") represents a contingent right to receive one share of the Issuer's common stock and are granted pursuant to the Issuer's 2018 Equity Incentive Plan (as amended). F2: Provided the Reporting Person continues to be providing service to the Issuer on the following dates, the DRSUs shall vest on the earlier of: (i) the first anniversary of the Transaction Date; or (ii) the day prior to the Issuer's next annual shareholder meeting. Notwithstanding the vesting, the issuance of the common stock will be deferred until the earlier of (i) three months after the Reporting Person's resignation or removal from the Board of Directors or no longer providing service because of death or disability, (ii) a change in control (as defined in the DRSU agreement) or (iii) ten years from the Transaction Date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each deferred restricted stock unit ("DRSU") represents a contingent right to receive one share of the Issuer's common stock and are granted pursuant to the Issuer's 2018 Equity Incentive Plan (as amended).
F2: Provided the Reporting Person continues to be providing service to the Issuer on the following dates, the DRSUs shall vest on the earlier of: (i) the first anniversary of the Transaction Date; or (ii) the day prior to the Issuer's next annual shareholder meeting. Notwithstanding the vesting, the issuance of the common stock will be deferred until the earlier of (i) three months after the Reporting Person's resignation or removal from the Board of Directors or no longer providing service because of death or disability, (ii) a change in control (as defined in the DRSU agreement) or (iii) ten years from the Transaction Date.
Passage BIO, Inc.
Report date May 19, 2026 · Filed May 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.08 · Expires 2036-05-19 | Direct | 10,539 |
Reported balance
After 2026-05-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-19 · Grant · Acquired 10,539 · Balance 10,539 F1: The stock option vests in full on the earlier of: (i) the one year anniversary of the grant date or (ii) the date of the issuer's 2027 Annual Meeting of its stockholders, subject to the reporting person's continuous service to the issuer on such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests in full on the earlier of: (i) the one year anniversary of the grant date or (ii) the date of the issuer's 2027 Annual Meeting of its stockholders, subject to the reporting person's continuous service to the issuer on such date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Turning Point Therapeutics, Inc.
Report date August 17, 2022 · Filed August 17, 2022
Section 16 reporting ended · disclosed 2022-08-17. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-08-17 transaction · row 1
1 source rowRow 1 · 2022-08-17 · Disposition to issuer · Disposed 110,959 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 2, 2022, by and among Turning Point Therapeutics, Inc. (the "Issuer"), Bristol-Myers Squibb Company ("BMS") and Rhumba Merger Sub Inc., a wholly owned subsidiary of BMS ("Purchaser"), on August 17, 2022, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of BMS (the "Merger"). At the effective time of the Merger, each issued and outstanding Share was cancelled in exchange for $76.00 per Share in cash, without interest, subject to any applicable withholding of taxes (the "Cash Amount"). Pursuant to the terms of the Merger Agreement, the Shares were tendered and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive the Cash Amount. F2: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding restricted stock unit award ("RSU") whether vested or unvested was cancelled and converted into the right to receive cash, without interest, in an amount equal to $76.00 per Share issuable in settlement of such RSU immediately before the effective time of the Merger, net of any withholding taxes required to be deducted and withheld by applicable law. F3: Includes 629 shares acquired on June 10, 2022 pursuant to the Issuer's Employee Stock Purchase Plan. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.20 · Expires 2028-06-05 | Direct | 0 |
Reported balance
After 2022-08-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-08-17 · Disposition to issuer · Disposed 173,389 · Balance 0 F4: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $76.00 per Share over (y) the exercise price payable per Share under such option, net of any withholding taxes required to be deducted and withheld by applicable law. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.20 · Expires 2028-06-05 | Direct | 0 |
Reported balance
After 2022-08-17 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-08-17 · Disposition to issuer · Disposed 67,575 · Balance 0 F4: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $76.00 per Share over (y) the exercise price payable per Share under such option, net of any withholding taxes required to be deducted and withheld by applicable law. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.12 · Expires 2028-11-05 | Direct | 0 |
Reported balance
After 2022-08-17 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-08-17 · Disposition to issuer · Disposed 989,971 · Balance 0 F4: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $76.00 per Share over (y) the exercise price payable per Share under such option, net of any withholding taxes required to be deducted and withheld by applicable law. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.43 · Expires 2029-02-19 | Direct | 0 |
Reported balance
After 2022-08-17 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-08-17 · Disposition to issuer · Disposed 155,844 · Balance 0 F4: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $76.00 per Share over (y) the exercise price payable per Share under such option, net of any withholding taxes required to be deducted and withheld by applicable law. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $63.33 · Expires 2030-01-05 | Direct | 0 |
Reported balance
After 2022-08-17 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-08-17 · Disposition to issuer · Disposed 325,000 · Balance 0 F4: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $76.00 per Share over (y) the exercise price payable per Share under such option, net of any withholding taxes required to be deducted and withheld by applicable law. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $140.01 · Expires 2031-02-07 | Direct | 0 |
Reported balance
After 2022-08-17 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2022-08-17 · Disposition to issuer · Disposed 101,775 · Balance 0 F5: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option with an exercise price equal to or greater than $76.00, was cancelled without any consideration in respect of such cancelled option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $37.68 · Expires 2032-02-08 | Direct | 0 |
Reported balance
After 2022-08-17 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2022-08-17 · Disposition to issuer · Disposed 224,640 · Balance 0 F4: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $76.00 per Share over (y) the exercise price payable per Share under such option, net of any withholding taxes required to be deducted and withheld by applicable law. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 2, 2022, by and among Turning Point Therapeutics, Inc. (the "Issuer"), Bristol-Myers Squibb Company ("BMS") and Rhumba Merger Sub Inc., a wholly owned subsidiary of BMS ("Purchaser"), on August 17, 2022, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of BMS (the "Merger"). At the effective time of the Merger, each issued and outstanding Share was cancelled in exchange for $76.00 per Share in cash, without interest, subject to any applicable withholding of taxes (the "Cash Amount"). Pursuant to the terms of the Merger Agreement, the Shares were tendered and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive the Cash Amount.
F2: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding restricted stock unit award ("RSU") whether vested or unvested was cancelled and converted into the right to receive cash, without interest, in an amount equal to $76.00 per Share issuable in settlement of such RSU immediately before the effective time of the Merger, net of any withholding taxes required to be deducted and withheld by applicable law.
F3: Includes 629 shares acquired on June 10, 2022 pursuant to the Issuer's Employee Stock Purchase Plan.
F4: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $76.00 per Share over (y) the exercise price payable per Share under such option, net of any withholding taxes required to be deducted and withheld by applicable law.
F5: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option with an exercise price equal to or greater than $76.00, was cancelled without any consideration in respect of such cancelled option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 16, 2026 Filed Jun 18, 2026 21:16 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | GrantDeferred Restricted Stock Unit · Derivative | 90,316 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-075858 · tm2618145-3_4seq1.xml · derivative · entry 1 Countouriotis Athena · CIK 0001571469 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,316 Underlying: Common Stock · 90,316 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred restricted stock unit ("DRSU") represents a contingent right to receive one share of the Issuer's common stock and are granted pursuant to the Issuer's 2018 Equity Incentive Plan (as amended). F2 · derivative.exercise_date: Provided the Reporting Person continues to be providing service to the Issuer on the following dates, the DRSUs shall vest on the earlier of: (i) the first anniversary of the Transaction Date; or (ii) the day prior to the Issuer's next annual shareholder meeting. Notwithstanding the vesting, the issuance of the common stock will be deferred until the earlier of (i) three months after the Reporting Person's resignation or removal from the Board of Directors or no longer providing service because of death or disability, (ii) a change in control (as defined in the DRSU agreement) or (iii) ten years from the Transaction Date. F2 · derivative.expiration_date: Provided the Reporting Person continues to be providing service to the Issuer on the following dates, the DRSUs shall vest on the earlier of: (i) the first anniversary of the Transaction Date; or (ii) the day prior to the Issuer's next annual shareholder meeting. Notwithstanding the vesting, the issuance of the common stock will be deferred until the earlier of (i) three months after the Reporting Person's resignation or removal from the Board of Directors or no longer providing service because of death or disability, (ii) a change in control (as defined in the DRSU agreement) or (iii) ten years from the Transaction Date. Read SEC document |
| June 02, 2026 Filed Jun 4, 2026 22:10 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 7,490 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-040922 · wk-form4_1780611012.xml · nonDerivative · entry 1 Countouriotis Athena · CIK 0001571469 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,040 F1 · price: Restricted stock units granted on June 2, 2026. Price not applicable. Read SEC document |
| May 19, 2026 Filed May 21, 2026 20:10 UTC | Passage BIO, Inc. PASG · Entity 7829 | GrantDirector Stock Option (right to buy) · Derivative | 10,539 | $0.00 Strike: $5.08 | $0.00 |
DisclosureSEC source: 0001571469-26-000002 · form4-05212026_080534.xml · derivative · entry 1 Countouriotis Athena · CIK 0001571469 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,539 Underlying: Common Stock · 10,539 shares Expires 2036-05-19 F1 · derivative.exercise_date: The stock option vests in full on the earlier of: (i) the one year anniversary of the grant date or (ii) the date of the issuer's 2027 Annual Meeting of its stockholders, subject to the reporting person's continuous service to the issuer on such date. Read SEC document |
| June 13, 2025 Filed Jun 17, 2025 20:09 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | GrantDeferred Restricted Stock Unit · Derivative | 67,546 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-060254 · tm2518181-5_4seq1.xml · derivative · entry 1 Countouriotis Athena · CIK 0001571469 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,546 Underlying: Common Stock · 67,546 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred restricted stock unit ("DRSU") represents a contingent right to receive one share of the Issuer's common stock and are granted pursuant to the Issuer's 2018 Equity Incentive Plan (as amended). F2 · derivative.exercise_date: Provided the Reporting Person continues to be providing service to the Issuer on the following dates, the DRSUs shall vest on the earlier of: (i) the first anniversary of the Transaction Date; or (2) the day prior to the Issuer's next annual shareholder meeting. Notwithstanding the vesting, the issuance of the common stock will be deferred until the earlier of (i) three months after the Reported Person's resignation or removal from the Board of Directors or no longer providing service because of death or disability, (ii) a change in control (as defined in the DRSU agreement) or (iii) ten years from the Transaction Date. F2 · derivative.expiration_date: Provided the Reporting Person continues to be providing service to the Issuer on the following dates, the DRSUs shall vest on the earlier of: (i) the first anniversary of the Transaction Date; or (2) the day prior to the Issuer's next annual shareholder meeting. Notwithstanding the vesting, the issuance of the common stock will be deferred until the earlier of (i) three months after the Reported Person's resignation or removal from the Board of Directors or no longer providing service because of death or disability, (ii) a change in control (as defined in the DRSU agreement) or (iii) ten years from the Transaction Date. Read SEC document |
| May 28, 2025 Filed May 30, 2025 23:30 UTC | Passage BIO, Inc. PASG · Entity 7829 | GrantDirector Stock Option (right to buy) · Derivative | 201,857 | $0.00 Strike: $0.36 | $0.00 |
DisclosureSEC source: 0001415889-25-015058 · form4-05302025_110515.xml · derivative · entry 1 Countouriotis Athena · CIK 0001571469 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 201,857 Underlying: Common Stock · 201,857 shares Expires 2035-05-28 F1 · derivative.exercise_date: The stock option vests in full on the earlier of: (i) the one year anniversary of the grant date or (ii) the date of the issuer's 2026 Annual Meeting of its stockholders, subject to the reporting person's continuous service to the issuer on such date. Read SEC document |
| May 20, 2025 Filed May 22, 2025 20:52 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 6,650 | $0.00 | $0.00 |
DisclosureSEC source: 0001048477-25-000066 · wk-form4_1747947154.xml · nonDerivative · entry 1 Countouriotis Athena · CIK 0001571469 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,550 F1 · price: Restricted stock units granted on May 20, 2025. Price not applicable. Read SEC document |
| June 11, 2024 Filed Jun 13, 2024 22:03 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | GrantDeferred Restricted Stock Unit · Derivative | 49,303 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-071374 · tm2417165-5_4seq1.xml · derivative · entry 1 Countouriotis Athena · CIK 0001571469 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,303 Underlying: Common Stock · 49,303 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred restricted stock unit ("DRSU") represents a contingent right to receive one share of the Issuer's common stock and are granted pursuant to the Issuer's 2018 Equity Incentive Plan (as amended). F2 · derivative.exercise_date: Provided the Reporting Person continues to be providing service to the Issuer on the following dates, the DRSUs shall vest on the earlier of: (i) the first anniversary of the Transaction Date; or (2) the day prior to the Issuer's next annual shareholder meeting. Notwithstanding the vesting, the issuance of the common stock will be deferred until the earlier of (i) three months after the Reported Person's resignation or removal from the Board of Directors or no longer providing service because of death or disability, (ii) a change in control (as defined in the DRSU agreement) or (iii) ten years from the Transaction Date. F2 · derivative.expiration_date: Provided the Reporting Person continues to be providing service to the Issuer on the following dates, the DRSUs shall vest on the earlier of: (i) the first anniversary of the Transaction Date; or (2) the day prior to the Issuer's next annual shareholder meeting. Notwithstanding the vesting, the issuance of the common stock will be deferred until the earlier of (i) three months after the Reported Person's resignation or removal from the Board of Directors or no longer providing service because of death or disability, (ii) a change in control (as defined in the DRSU agreement) or (iii) ten years from the Transaction Date. Read SEC document |
| May 21, 2024 Filed May 23, 2024 21:14 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 4,720 | $0.00 | $0.00 |
DisclosureSEC source: 0001048477-24-000096 · wk-form4_1716498842.xml · nonDerivative · entry 1 Countouriotis Athena · CIK 0001571469 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,900 F1 · price: Restricted stock units granted on May 21, 2024. Price not applicable. Read SEC document |
| May 21, 2024 Filed May 23, 2024 21:43 UTC | Passage BIO, Inc. PASG · Entity 7829 | GrantDirector Stock Option (right to buy) · Derivative | 47,693 | $0.00 Strike: $1.28 | $0.00 |
DisclosureSEC source: 0001415889-24-014333 · form4-05232024_090550.xml · derivative · entry 1 Countouriotis Athena · CIK 0001571469 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,693 Underlying: Common Stock · 47,693 shares Expires 2034-05-21 F1 · derivative.exercise_date: The stock option vests in full on the earlier of: (i) the one year anniversary of the grant date or (ii) the date of the issuer's 2025 Annual Meeting of its stockholders, subject to the reporting person's continuous service to the issuer on such date. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 22:50 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | GrantDeferred Restricted Stock Unit · Derivative | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-031105 · tm248017d1_4seq1.xml · derivative · entry 1 Countouriotis Athena · CIK 0001571469 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred restricted stock unit ("DRSU") represents a contingent right to receive one share of the Issuer's common stock and are granted pursuant to the Issuer's 2018 Equity Incentive Plan (as amended). F2 · derivative.exercise_date: 50% of the RSUs will vest on the 6-month anniversary of the date of grant and the remaining RSUs will vest on the one-year anniversary of the date of grant. Notwithstanding the vesting, the issuance of the common stock will be deferred until the earlier of (i) three months after the Reported Person's resignation or removal from the Board of Directors or no longer providing service because of death or disability, (ii) a change in control (as defined in the DRSU agreement) or (iii) ten years from the Transaction Date. F2 · derivative.expiration_date: 50% of the RSUs will vest on the 6-month anniversary of the date of grant and the remaining RSUs will vest on the one-year anniversary of the date of grant. Notwithstanding the vesting, the issuance of the common stock will be deferred until the earlier of (i) three months after the Reported Person's resignation or removal from the Board of Directors or no longer providing service because of death or disability, (ii) a change in control (as defined in the DRSU agreement) or (iii) ten years from the Transaction Date. Read SEC document |
| December 27, 2023 Filed Dec 28, 2023 18:03 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 2,180 | $0.00 | $0.00 |
DisclosureSEC source: 0001048477-23-000068 · wk-form4_1703786629.xml · nonDerivative · entry 1 Countouriotis Athena · CIK 0001571469 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,180 F1 · price: Restricted stock units granted on December 27, 2023. Price not applicable. Read SEC document |
| June 06, 2023 Filed Jun 8, 2023 22:22 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | GrantDeferred Restricted Stock Unit · Derivative | 51,955 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-069509 · tm2318216-6_4seq1.xml · derivative · entry 1 Countouriotis Athena · CIK 0001571469 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,955 Underlying: Common Stock · 51,955 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred restricted stock unit ("DRSU") represents a contingent right to receive one share of the Issuer's common stock and are granted pursuant to the Issuer's 2018 Equity Incentive Plan (as amended). F2 · derivative.exercise_date: Provided the Reporting Person continues to be providing service to the Issuer on the following dates, the DRSUs shall vest on the earlier of: (i) the first anniversary of the Transaction Date; or (2) the day prior to the Issuer's next annual shareholder meeting. Notwithstanding the vesting, the issuance of the common stock will be deferred until the earlier of (i) three months after the Reported Person's resignation or removal from the Board of Directors or no longer providing service because of death or disability, (ii) a change in control (as defined in the DRSU agreement) or (iii) ten years from the Transaction Date. F2 · derivative.expiration_date: Provided the Reporting Person continues to be providing service to the Issuer on the following dates, the DRSUs shall vest on the earlier of: (i) the first anniversary of the Transaction Date; or (2) the day prior to the Issuer's next annual shareholder meeting. Notwithstanding the vesting, the issuance of the common stock will be deferred until the earlier of (i) three months after the Reported Person's resignation or removal from the Board of Directors or no longer providing service because of death or disability, (ii) a change in control (as defined in the DRSU agreement) or (iii) ten years from the Transaction Date. Read SEC document |
| May 25, 2023 Filed May 26, 2023 20:22 UTC | Passage BIO, Inc. PASG · Entity 7829 | GrantDirector Stock Option (Right to Buy) · Derivative | 24,000 | $0.00 Strike: $1.00 | $0.00 |
DisclosureSEC source: 0001209191-23-032542 · doc4.xml · derivative · entry 1 Countouriotis Athena · CIK 0001571469 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2033-05-24 F1 · derivative.exercise_date: The stock option vests in full on the earlier of: (i) the one year anniversary of the grant date or (ii) the date of the issuer's 2024 Annual Meeting of its stockholders, subject to the reporting person's continuous service to the issuer on such date. Read SEC document |
| August 17, 2022 Filed Aug 17, 2022 20:23 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | Disposition to issuerStock Option (right to buy) · Derivative | 224,640 | Not disclosed Strike: $37.68 | Not disclosed |
DisclosureSEC source: 0001209191-22-046258 · doc4.xml · derivative · entry 8 Countouriotis Athena · CIK 0001571469 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 224,640 shares Expires 2032-02-08 F4 · price: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $76.00 per Share over (y) the exercise price payable per Share under such option, net of any withholding taxes required to be deducted and withheld by applicable law. F4 · derivative.exercise_date: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $76.00 per Share over (y) the exercise price payable per Share under such option, net of any withholding taxes required to be deducted and withheld by applicable law. Read SEC document |
| August 17, 2022 Filed Aug 17, 2022 20:23 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | Disposition to issuerStock Option (right to buy) · Derivative | 101,775 | Not disclosed Strike: $140.01 | Not disclosed |
DisclosureSEC source: 0001209191-22-046258 · doc4.xml · derivative · entry 7 Countouriotis Athena · CIK 0001571469 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 101,775 shares Expires 2031-02-07 F5 · price: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option with an exercise price equal to or greater than $76.00, was cancelled without any consideration in respect of such cancelled option. F5 · derivative.exercise_date: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option with an exercise price equal to or greater than $76.00, was cancelled without any consideration in respect of such cancelled option. Read SEC document |
| August 17, 2022 Filed Aug 17, 2022 20:23 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | Disposition to issuerStock Option (right to buy) · Derivative | 325,000 | Not disclosed Strike: $63.33 | Not disclosed |
DisclosureSEC source: 0001209191-22-046258 · doc4.xml · derivative · entry 6 Countouriotis Athena · CIK 0001571469 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 325,000 shares Expires 2030-01-05 F4 · price: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $76.00 per Share over (y) the exercise price payable per Share under such option, net of any withholding taxes required to be deducted and withheld by applicable law. F4 · derivative.exercise_date: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $76.00 per Share over (y) the exercise price payable per Share under such option, net of any withholding taxes required to be deducted and withheld by applicable law. Read SEC document |
| August 17, 2022 Filed Aug 17, 2022 20:23 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | Disposition to issuerStock Option (right to buy) · Derivative | 155,844 | Not disclosed Strike: $7.43 | Not disclosed |
DisclosureSEC source: 0001209191-22-046258 · doc4.xml · derivative · entry 5 Countouriotis Athena · CIK 0001571469 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 155,844 shares Expires 2029-02-19 F4 · price: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $76.00 per Share over (y) the exercise price payable per Share under such option, net of any withholding taxes required to be deducted and withheld by applicable law. F4 · derivative.exercise_date: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $76.00 per Share over (y) the exercise price payable per Share under such option, net of any withholding taxes required to be deducted and withheld by applicable law. Read SEC document |
| August 17, 2022 Filed Aug 17, 2022 20:23 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | Disposition to issuerStock Option (right to buy) · Derivative | 989,971 | Not disclosed Strike: $5.12 | Not disclosed |
DisclosureSEC source: 0001209191-22-046258 · doc4.xml · derivative · entry 4 Countouriotis Athena · CIK 0001571469 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 989,971 shares Expires 2028-11-05 F4 · price: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $76.00 per Share over (y) the exercise price payable per Share under such option, net of any withholding taxes required to be deducted and withheld by applicable law. F4 · derivative.exercise_date: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $76.00 per Share over (y) the exercise price payable per Share under such option, net of any withholding taxes required to be deducted and withheld by applicable law. Read SEC document |
| August 17, 2022 Filed Aug 17, 2022 20:23 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | Disposition to issuerStock Option (right to buy) · Derivative | 67,575 | Not disclosed Strike: $3.20 | Not disclosed |
DisclosureSEC source: 0001209191-22-046258 · doc4.xml · derivative · entry 3 Countouriotis Athena · CIK 0001571469 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 67,575 shares Expires 2028-06-05 F4 · price: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $76.00 per Share over (y) the exercise price payable per Share under such option, net of any withholding taxes required to be deducted and withheld by applicable law. F4 · derivative.exercise_date: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $76.00 per Share over (y) the exercise price payable per Share under such option, net of any withholding taxes required to be deducted and withheld by applicable law. Read SEC document |
| August 17, 2022 Filed Aug 17, 2022 20:23 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | Disposition to issuerStock Option (right to buy) · Derivative | 173,389 | Not disclosed Strike: $3.20 | Not disclosed |
DisclosureSEC source: 0001209191-22-046258 · doc4.xml · derivative · entry 2 Countouriotis Athena · CIK 0001571469 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 173,389 shares Expires 2028-06-05 F4 · price: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $76.00 per Share over (y) the exercise price payable per Share under such option, net of any withholding taxes required to be deducted and withheld by applicable law. F4 · derivative.exercise_date: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $76.00 per Share over (y) the exercise price payable per Share under such option, net of any withholding taxes required to be deducted and withheld by applicable law. Read SEC document |
| August 17, 2022 Filed Aug 17, 2022 20:23 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | Disposition to issuerCommon Stock | 110,959 | $76.00 | $8,432,884.00 |
DisclosureSEC source: 0001209191-22-046258 · doc4.xml · nonDerivative · entry 1 Countouriotis Athena · CIK 0001571469 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 2, 2022, by and among Turning Point Therapeutics, Inc. (the "Issuer"), Bristol-Myers Squibb Company ("BMS") and Rhumba Merger Sub Inc., a wholly owned subsidiary of BMS ("Purchaser"), on August 17, 2022, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of BMS (the "Merger"). At the effective time of the Merger, each issued and outstanding Share was cancelled in exchange for $76.00 per Share in cash, without interest, subject to any applicable withholding of taxes (the "Cash Amount"). Pursuant to the terms of the Merger Agreement, the Shares were tendered and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive the Cash Amount. F2 · shares: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding restricted stock unit award ("RSU") whether vested or unvested was cancelled and converted into the right to receive cash, without interest, in an amount equal to $76.00 per Share issuable in settlement of such RSU immediately before the effective time of the Merger, net of any withholding taxes required to be deducted and withheld by applicable law. F3 · shares: Includes 629 shares acquired on June 10, 2022 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| June 10, 2022 Filed Jun 14, 2022 21:03 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | GrantDeferred Restricted Stock Unit · Derivative | 51,204 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-071056 · tm2218366-7_4seq1.xml · derivative · entry 1 Countouriotis Athena · CIK 0001571469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,204 Underlying: Common Stock · 51,204 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred restricted stock unit ("DRSU") represents a contingent right to receive one share of the Issuer's common stock and are granted pursuant to the Issuer's 2018 Equity Incentive Plan (as amended). F2 · derivative.exercise_date: Provided the Reporting Person continues to be providing service to the Issuer on the following dates, the DRSUs shall vest on the earlier of: (i) the first anniversary of the Transaction Date; or (2) the day prior to the Issuer's next annual shareholder meeting. Notwithstanding the vesting, the issuance of the common stock will be deferred until the earlier of (i) three months after the Reported Person's resignation or removal from the Board of Directors or no longer providing service because of death or disability, (ii) a change in control (as defined in the DRSU agreement) or (iii) ten years from the Transaction Date. F2 · derivative.expiration_date: Provided the Reporting Person continues to be providing service to the Issuer on the following dates, the DRSUs shall vest on the earlier of: (i) the first anniversary of the Transaction Date; or (2) the day prior to the Issuer's next annual shareholder meeting. Notwithstanding the vesting, the issuance of the common stock will be deferred until the earlier of (i) three months after the Reported Person's resignation or removal from the Board of Directors or no longer providing service because of death or disability, (ii) a change in control (as defined in the DRSU agreement) or (iii) ten years from the Transaction Date. Read SEC document |
| May 26, 2022 Filed May 31, 2022 20:20 UTC | Passage BIO, Inc. PASG · Entity 7829 | GrantDirector Stock Option (Right to Buy) · Derivative | 24,000 | $0.00 Strike: $1.76 | $0.00 |
DisclosureSEC source: 0001209191-22-032807 · doc4.xml · derivative · entry 1 Countouriotis Athena · CIK 0001571469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2032-05-25 F1 · derivative.exercise_date: The stock option vests in full on the earlier of: (i) the one year anniversary of the grant date or (ii) the date of the issuer's 2023 Annual Meeting of its stockholders, subject to the reporting person's continuous service to the issuer on such date. Read SEC document |
| February 09, 2022 Filed Feb 11, 2022 23:07 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | GrantStock Option (right to buy) · Derivative | 224,640 | $0.00 Strike: $37.68 | $0.00 |
DisclosureSEC source: 0001209191-22-008979 · doc4.xml · derivative · entry 3 Countouriotis Athena · CIK 0001571469 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 224,640 Underlying: Common Stock · 224,640 shares Expires 2032-02-08 F4 · derivative.exercise_date: 1/48th of the shares vest monthly following February 9, 2022. Read SEC document |
| February 09, 2022 Filed Feb 11, 2022 23:07 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | GrantCommon Stock | 62,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-008979 · doc4.xml · nonDerivative · entry 2 Countouriotis Athena · CIK 0001571469 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,330 F3 · shares: Represents restricted stock unit award granted under the Issuer's 2019 Equity Plan. Read SEC document |
| February 09, 2022 Filed Feb 11, 2022 23:07 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 2,971 | $36.30 | $107,847.30 |
DisclosureSEC source: 0001209191-22-008979 · doc4.xml · nonDerivative · entry 1 Countouriotis Athena · CIK 0001571469 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,930 F1 · kind: Sale of shares of common stock to cover tax withholding obligations associated with the vesting of a restricted stock unit award granted to Reporting Person on February 8, 2021. F2 · balance_after: The Reporting Person acquired 706 shares on June 10, 2021 pursuant to the Issuer's Employee Stock Purchase Plan (the "ESPP"). Read SEC document |
| June 29, 2021 Filed Jul 1, 2021 20:17 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | GrantStock Option (right to buy) · Derivative | 35,000 | $0.00 Strike: $26.33 | $0.00 |
DisclosureSEC source: 0001104659-21-088245 · tm2121236-1_4seq1.xml · derivative · entry 1 Countouriotis Athena · CIK 0001571469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2031-06-29 F1 · derivative.exercise_date: These options are exercisable in four equal quarterly installments of 8,750 each following the date of grant, such that the options will be fully vested and exercisable on June 29, 2022. Read SEC document |
| May 27, 2021 Filed May 28, 2021 21:50 UTC | Passage BIO, Inc. PASG · Entity 7829 | GrantDirector Stock Option (Right to Buy) · Derivative | 16,918 | $0.00 Strike: $13.83 | $0.00 |
DisclosureSEC source: 0001209191-21-036616 · doc4.xml · derivative · entry 1 Countouriotis Athena · CIK 0001571469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,918 Underlying: Common Stock · 16,918 shares Expires 2031-05-26 F1 · derivative.exercise_date: The stock option vests as of 1/12 of the total shares monthly beginning on June 27, 2021 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| February 11, 2021 Filed Feb 12, 2021 01:28 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | Exercise / conversionStock Option (right to buy) · Derivative | 8,942 | $0.00 Strike: $3.20 | $0.00 |
DisclosureSEC source: 0001209191-21-009931 · doc4.xml · derivative · entry 21 Countouriotis Athena · CIK 0001571469 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,389 Underlying: Common Stock · 8,942 shares Expires 2028-06-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020. F15 · derivative.exercise_date: 25% of the shares vested on May 7, 2019 and 1/48th of the shares vest monthly thereafter over the next three years. Read SEC document |
| February 11, 2021 Filed Feb 12, 2021 01:28 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 3,052 | $138.55 | $422,854.60 |
DisclosureSEC source: 0001209191-21-009931 · doc4.xml · nonDerivative · entry 17 Countouriotis Athena · CIK 0001571469 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,195 F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020. F14 · price: The weighted average sale price for the transaction reported was $138.55, and the range of prices were between $138.09 and $139.00. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| February 11, 2021 Filed Feb 12, 2021 01:28 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 1,571 | $137.66 | $216,263.86 |
DisclosureSEC source: 0001209191-21-009931 · doc4.xml · nonDerivative · entry 16 Countouriotis Athena · CIK 0001571469 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,247 F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020. F13 · price: The weighted average sale price for the transaction reported was $137.66, and the range of prices were between $137.025 and $138.00. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| February 11, 2021 Filed Feb 12, 2021 01:28 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 4,319 | $136.45 | $589,327.55 |
DisclosureSEC source: 0001209191-21-009931 · doc4.xml · nonDerivative · entry 15 Countouriotis Athena · CIK 0001571469 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,818 F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020. F12 · price: The weighted average sale price for the transaction reported was $136.45, and the range of prices were between $136.00 and $137.00. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| February 11, 2021 Filed Feb 12, 2021 01:28 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | Exercise / conversionCommon Stock | 8,942 | $3.20 | $28,614.40 |
DisclosureSEC source: 0001209191-21-009931 · doc4.xml · nonDerivative · entry 14 Countouriotis Athena · CIK 0001571469 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,137 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 01:28 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | Exercise / conversionStock Option (right to buy) · Derivative | 25,392 | $0.00 Strike: $3.20 | $0.00 |
DisclosureSEC source: 0001209191-21-009931 · doc4.xml · derivative · entry 20 Countouriotis Athena · CIK 0001571469 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,331 Underlying: Common Stock · 25,392 shares Expires 2028-06-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020. F15 · derivative.exercise_date: 25% of the shares vested on May 7, 2019 and 1/48th of the shares vest monthly thereafter over the next three years. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 01:28 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 433 | $138.19 | $59,836.27 |
DisclosureSEC source: 0001209191-21-009931 · doc4.xml · nonDerivative · entry 13 Countouriotis Athena · CIK 0001571469 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,195 F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020. F11 · price: The weighted average sale price for the transaction reported was $138.19, and the range of prices were between $138.05 and $138.425. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 01:28 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 2,081 | $137.46 | $286,054.26 |
DisclosureSEC source: 0001209191-21-009931 · doc4.xml · nonDerivative · entry 12 Countouriotis Athena · CIK 0001571469 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,628 F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020. F10 · price: The weighted average sale price for the transaction reported was $137.46, and the range of prices were between $137.04 and $138.04. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 01:28 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 16,626 | $136.42 | $2,268,118.92 |
DisclosureSEC source: 0001209191-21-009931 · doc4.xml · nonDerivative · entry 11 Countouriotis Athena · CIK 0001571469 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,709 F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020. F9 · price: The weighted average sale price for the transaction reported was $136.42, and the range of prices were between $136.02 and $137.02. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 01:28 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 5,227 | $135.72 | $709,408.44 |
DisclosureSEC source: 0001209191-21-009931 · doc4.xml · nonDerivative · entry 10 Countouriotis Athena · CIK 0001571469 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,335 F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020. F8 · price: The weighted average sale price for the transaction reported was $135.72, and the range of prices were between $135.015 and $136.015. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 01:28 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 1,025 | $134.34 | $137,698.50 |
DisclosureSEC source: 0001209191-21-009931 · doc4.xml · nonDerivative · entry 9 Countouriotis Athena · CIK 0001571469 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,562 F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020. F7 · price: The weighted average sale price for the transaction reported was $134.34, and the range of prices were between $134.00 and $135.00. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 01:28 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | Exercise / conversionCommon Stock | 25,392 | $3.20 | $81,254.40 |
DisclosureSEC source: 0001209191-21-009931 · doc4.xml · nonDerivative · entry 8 Countouriotis Athena · CIK 0001571469 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,587 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020. Read SEC document |
| February 09, 2021 Filed Feb 12, 2021 01:28 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | Exercise / conversionStock Option (right to buy) · Derivative | 7,666 | $0.00 Strike: $3.20 | $0.00 |
DisclosureSEC source: 0001209191-21-009931 · doc4.xml · derivative · entry 19 Countouriotis Athena · CIK 0001571469 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,575 Underlying: Common Stock · 7,666 shares Expires 2028-06-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020. F16 · derivative.exercise_date: 25% of the shares vested on June 29, 2019 and 1/48th of the shares vest monthly thereafter over the next three years. Read SEC document |
| February 09, 2021 Filed Feb 12, 2021 01:28 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | Exercise / conversionStock Option (right to buy) · Derivative | 18,000 | $0.00 Strike: $3.20 | $0.00 |
DisclosureSEC source: 0001209191-21-009931 · doc4.xml · derivative · entry 18 Countouriotis Athena · CIK 0001571469 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,723 Underlying: Common Stock · 18,000 shares Expires 2028-06-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020. F15 · derivative.exercise_date: 25% of the shares vested on May 7, 2019 and 1/48th of the shares vest monthly thereafter over the next three years. Read SEC document |
| February 09, 2021 Filed Feb 12, 2021 01:28 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 1,104 | $140.24 | $154,824.96 |
DisclosureSEC source: 0001209191-21-009931 · doc4.xml · nonDerivative · entry 7 Countouriotis Athena · CIK 0001571469 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,195 F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020. F6 · price: The weighted average sale price for the transaction reported was $140.24, and the range of prices were between $140.24 and $140.39. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| February 09, 2021 Filed Feb 12, 2021 01:28 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 13,290 | $139.69 | $1,856,480.10 |
DisclosureSEC source: 0001209191-21-009931 · doc4.xml · nonDerivative · entry 6 Countouriotis Athena · CIK 0001571469 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,299 F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020. F5 · price: The weighted average sale price for the transaction reported was $139.69, and the range of prices were between $139.235 and $140.10. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| February 09, 2021 Filed Feb 12, 2021 01:28 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 4,969 | $138.66 | $689,001.54 |
DisclosureSEC source: 0001209191-21-009931 · doc4.xml · nonDerivative · entry 5 Countouriotis Athena · CIK 0001571469 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,589 F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020. F4 · price: The weighted average sale price for the transaction reported was $138.66, and the range of prices were between $138.09 and $139.085. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| February 09, 2021 Filed Feb 12, 2021 01:28 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 103 | $137.58 | $14,170.74 |
DisclosureSEC source: 0001209191-21-009931 · doc4.xml · nonDerivative · entry 4 Countouriotis Athena · CIK 0001571469 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,558 F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020. F3 · price: The weighted average sale price for the transaction reported was $137.58, and the range of prices were between $137.035 and $138. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| February 09, 2021 Filed Feb 12, 2021 01:28 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 6,200 | $136.29 | $844,998.00 |
DisclosureSEC source: 0001209191-21-009931 · doc4.xml · nonDerivative · entry 3 Countouriotis Athena · CIK 0001571469 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,661 F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020. F2 · price: The weighted average sale price for the transaction reported was $136.29, and the range of prices were between $136.00 and $137. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| February 09, 2021 Filed Feb 12, 2021 01:28 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | Exercise / conversionCommon Stock | 7,666 | $3.20 | $24,531.20 |
DisclosureSEC source: 0001209191-21-009931 · doc4.xml · nonDerivative · entry 2 Countouriotis Athena · CIK 0001571469 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,861 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020. Read SEC document |
| February 09, 2021 Filed Feb 12, 2021 01:28 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | Exercise / conversionCommon Stock | 18,000 | $3.20 | $57,600.00 |
DisclosureSEC source: 0001209191-21-009931 · doc4.xml · nonDerivative · entry 1 Countouriotis Athena · CIK 0001571469 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,195 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 22:52 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | GrantStock Option (right to buy) · Derivative | 101,775 | $0.00 Strike: $140.01 | $0.00 |
DisclosureSEC source: 0001209191-21-009357 · doc4.xml · derivative · entry 2 Countouriotis Athena · CIK 0001571469 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,775 Underlying: Common Stock · 101,775 shares Expires 2031-02-07 F3 · derivative.exercise_date: 1/48th of the shares vest monthly following February 8, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.